Live Webinar «AI in CAPA Effectiveness: An Expert Discussion»

This webinar has been cancelled. We’ll announce a new date soon. Thank you for your understanding.

Where automation ends, and executive accountability begins.

AI is transforming pharma quality operations, but adopting it successfully is a leadership decision, not just a technical one. Using CAPA effectiveness as a real-world use case, this expert panel will explore how senior quality leaders can move from AI pilots to trusted, scalable decision support without over-governing or creating blind trust in AI.

📍 Where: Live on Zoom
📆 When: 9th March
🕔 Time: 5:00 PM CET / 11:00 AM EST
🌍 Language: English

Webinar agenda

Here’s what you’ll walk away with:

What you’ll learn:

✅ How to approach AI in CAPA as an accountability and governance challenge

✅ Where human oversight must remain critical in AI-supported decisions

✅ How to prevent blind trust while still gaining value from AI insights

✅ What responsible AI adoption truly requires from quality leadership

Who will benefit from this webinar

This webinar is ideal for:

Pharma Quality Leaders & Managers
Risk and Compliance professionals
Pharma Executives & Senior Leadership
CAPA and Quality System Leaders
Digital & Transformation Leaders

Our speakers

Juan Torres

Former Chief Quality Officer at Biogen

Dr. Juan Torres is a NIIMBL Senior Fellow and President of Ingenuitas, a non-profit advancing innovative health solutions and STEM education. With 30+ years in biotechnology and pharmaceuticals, he specializes in quality systems innovation, biopharmaceutical development, and regulatory compliance. He served nearly two decades as Chief Quality Officer at Biogen and has held executive roles at Bayer and J&J. He now leads Futurum Biosciences, a consultancy enhancing biotech quality processes. Known for his integrity, global perspective, and mentorship, Juan holds PhDs in Biochemistry and Toxicology and completed postdoctoral work in Chemical Engineering at North Carolina State University.

David Grote

Vice President of Strategy at GrayMatter Partners

David Grote is a globally recognized biopharmaceutical leader and innovator, boasting over 30 years of success driving quality assurance and operations at major firms including Amgen, Teva Pharmaceuticals, and Immunocore. His career is distinguished by his proven ability to expedite product transitions from discovery to approved medicines and resolve high-stakes regulatory challenges, positioning him as a definitive authority in international GxP compliance. Currently, as Vice President of Strategy at GrayMatter Partners, Mr. Grote is pioneering the modernization of quality systems through the strategic deployment of artificial intelligence and advanced technologies.

Martin Lehmann

Chief Product Officer at Qualifyze

Martin Lehmann is Chief Product Officer at Qualifyze, where he leads product strategy, UX, and execution. He is responsible for driving the company’s evolution toward AI-powered audit and site risk management, with a strong focus on delivering superior customer value through data, automation, and scalable processes.Before joining Qualifyze, Martin spent 17 years in product, strategy, and technology leadership roles, primarily in regulated industries, where he worked extensively on risk management and compliance challenges. Martin’s ambition is to help build the world’s leading “supply chain trust layer” — enabling objective, data-driven decisions and industry collaboration.